Molecular Partners AG (MOLN)

5.71 +0.29 (+5.35%) USD  |  NASDAQ  |  Nov 22, 10:01
More

Molecular Partners Total Assets (Quarterly): 183.31M for Sept. 30, 2024

Total Assets (Quarterly) Chart

Historical Total Assets (Quarterly) Data

View and export this data back to 2014. Upgrade now.
Date Value
September 30, 2024 183.31M
June 30, 2024 189.80M
March 31, 2024 205.71M
December 31, 2023 236.15M
September 30, 2023 238.40M
June 30, 2023 256.31M
March 31, 2023 267.69M
December 31, 2022 282.87M
September 30, 2022 288.33M
June 30, 2022 313.61M
March 31, 2022 337.76M
December 31, 2021 188.89M
September 30, 2021 188.74M
June 30, 2021 224.74M
December 31, 2020 214.66M
June 30, 2020 77.10M
Date Value
December 31, 2019 108.30M
June 30, 2019 138.08M
June 30, 2019 138.08M
December 31, 2018 157.59M
June 30, 2018 127.73M
June 30, 2018 127.73M
December 31, 2017 148.26M
June 30, 2017 168.54M
June 30, 2017 168.54M
December 31, 2016 180.92M
June 30, 2016 204.76M
June 30, 2016 204.76M
December 31, 2015 221.96M
June 30, 2015 208.91M
June 30, 2015 208.91M
December 31, 2014 196.21M

Total Assets Definition

Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.

Read full definition.

Total Assets (Quarterly) Range, Past 5 Years

77.10M
Minimum
Jun 2020
337.76M
Maximum
Mar 2022
223.67M
Average
224.74M
Median
Jun 2021

Total Assets (Quarterly) Benchmarks

AC Immune SA 290.33M
CRISPR Therapeutics AG 2.256B
Addex Therapeutics Ltd 15.24M
NLS Pharmaceutics Ltd 1.194M
MoonLake Immunotherapeutics 518.21M

Total Assets (Quarterly) Related Metrics

Total Liabilities (Quarterly) 18.34M
Shareholders Equity (Quarterly) 164.96M
Current Ratio 14.33